Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DNA vs EVMN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EVMN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–4 Matrix Metrics)

EVMN Overall Winner 6-Pillar Tally: DNA 2 – 3 EVMN (1 Tie) Matrix Metrics: DNA 4 – 4 EVMN

As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over Ginkgo Bioworks Holdings, Inc. (DNA) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). DNA carries a Unified Composite Score of 56.0/100 (HOLD) at $8.50 (N/M Forward P/E, -202.5% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While DNA currently prints a higher short-term Unified Composite Score (56.0/100 HOLD vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -202.5% operating margin) and revenue trajectory (+0.0% vs. -5.7% YoY).
  • Technical & Structure Timing Caution: DNA is currently in a Breakdown options structure phase (RSI 41.0); meanwhile EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DNA vs EVMN
DNA NYSE
Ginkgo Bioworks Holdings, Inc.
Biological Products, (No Disgnostic Substances)
$8.50
-11.55% 1D
Market Cap $623.0M
TTM Revenue $131M
Forward P/E N/M
Beta / 30D Vol 3.14β · 152% Vol
Unified Composite Score
56.0 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.0 · SMA20: $10.73 · SMA50: $10.32
EVMN US Equity Head-to-Head Winner
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $315.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 118% Vol
Unified Composite Score
30.0 / 100 SELL
Tech 50.0 Fund 35.0 Flow 69.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.2 · SMA20: $6.45 · SMA50: $7.47

6-Pillar Scorecard Institutional Category Breakdown (DNA 2 – 3 EVMN)

Columns: Metric · DNA · EVMN
1. Valuation Multiples DNA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 7.2x N/M
2. Growth & Scale DNA
Revenue Growth (YoY) -5.7% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $131M N/A
Market Cap $623.0M $315.5M
3. Profitability & Quality EVMN
Gross Margin 69.8% N/A
Operating Margin -202.5% 0.0%
Net Profit Margin -192.0% 0.0%
Return on Equity (ROE) -58.2% -69.5%
4. Balance Sheet & Cash Flow EVMN
Cash Generation (TTM) -$174M -$75M
Cash Flow Margin N/A N/A
Net Cash / Leverage $313M Net Debt (1.01x D/E) $52M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EVMN
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 119.2% (34th %ile) 209.0% (53rd %ile)
Put/Call OI Skew 0.13x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DNA (4) vs EVMN (4)
Institutional Metric DNA EVMN Criterion Row Edge
Market Capitalization
Scale
$623.0M $315.5M Larger Scale DNA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-5.7% +0.0% Higher Growth EVMN
Operating Margin (TTM)
Profitability
-202.5% 0.0% Higher Margin EVMN
Net Profit Margin
Profitability
-192.0% 0.0% Higher Margin EVMN
Return on Equity (ROE)
Capital Efficiency
-58.2% -69.5% Higher ROE DNA
52-Week Range Position
Momentum
24% ($5–$18) 8% ($5–$33) Stronger Trend DNA
Beta / 30D Volatility
Risk Regime
3.14β · 152% Vol 1.05β · 118% Vol Lower Realized Risk EVMN
Unified Institutional Score
Composite Signal
56.0 / 100 (HOLD) 30.0 / 100 (SELL) Higher Composite DNA
Trailing 12M Revenue (USD)
Operating Scale
$131M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
69.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 7.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$174M ($313M Net Debt (1.01x D/E)) -$75M ($52M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EVMN +54.56 pp
DNA: -17.23% · EVMN: +37.33%
3M Horizon DNA +80.24 pp
DNA: +30.17% · EVMN: -50.07%
6M Horizon DNA +82.9 pp
DNA: +15.33% · EVMN: -67.57%
1Y Horizon DNA +67.28 pp
DNA: +6.25% · EVMN: -61.03%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DNA Revenue EVMN Revenue DNA Op. Margin EVMN Op. Margin Margin Leader
FY2019 $50M N/A -132.1% N/A DNA
FY2020 $80M N/A -178.8% N/A DNA
FY2021 $310M N/A -582.6% N/A DNA
FY2022 $480M N/A -462.4% N/A DNA
FY2023 $250M N/A -343.8% N/A DNA
FY2024 $230M $10M -246.5% -1000.2% DNA
FY2025 $170M $10M -185.3% -623.6% DNA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DNA BREAKDOWN
30d in phase · OBV DISTRIBUTION
Current IV 119.2%
IV Percentile 34th %ile
Put/Call OI Skew 0.13x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact DNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EVMN SURGE
5d in phase · OBV ACCUMULATION
Current IV 209.0%
IV Percentile 53rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact EVMN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $623.0M market capitalization and -202.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EVMN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $315.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DNA vs EVMN Key Questions & Quantitative Answers

As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over Ginkgo Bioworks Holdings, Inc. (DNA) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). DNA carries a Unified Composite Score of 56.0/100 (HOLD) at $8.50 (N/M Forward P/E, -202.5% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While DNA currently prints a higher short-term Unified Composite Score (56.0/100 HOLD vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -202.5% operating margin) and revenue trajectory (+0.0% vs. -5.7% YoY). Technical & Structure Timing Caution: DNA is currently in a Breakdown options structure phase (RSI 41.0); meanwhile EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DNA leads the Growth & Scale pillar: DNA posts -5.7% YoY revenue growth and +0.0% YoY earnings growth on $131M TTM revenue (69.8% gross margin, -202.5% operating margin), compared with EVMN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), DNA cumulative revenue shifted +240.0% while EVMN shifted +0.0%. In operating R&D and SG&A reinvestment, DNA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EVMN.

DNA screens cheaper on headline valuation multiples. DNA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.2x EV/Revenue (unreported FCF margin), whereas EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DNA (-58.2% ROE) versus EVMN (-69.5% ROE) capital efficiency.

In options market volatility and institutional positioning, DNA carries 119.2% implied volatility (34th %ile, Balanced (25th–60th %ile)), a 0.13x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.14β · 152% Vol realized risk). By comparison, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.